AVP and fetal growth restriction: The chronic administration of AVP in pregnant mice replicated pregnancy-specific hypertension, glomerular endotheliosis, proteinuria, and intrauterine growth restriction, thus supporting the role of AVP in PE progression and copeptin as an early biomarker for PE prediction [23••].